Clinical Trials | April 14, 2026
AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial
Highlights Mirvetuximab-based regimen promise
Highlights Mirvetuximab-based regimen promise
Its a major breakthrough for women’s ovarian cancer care in Europe
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Subscribe To Our Newsletter & Stay Updated
